TrialProstate cancer and prostatic diseases2026

Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK.

Ugo De Giorgi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.